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Abstract
Skeletal mass is maintained by a balance between formation
and resorption, cell proliferation and apoptosis. In vitro,
glucocorticoids (GCs) decrease extracellular signal-regulated
kinases (ERK) activation by mitogens, thus inhibiting
osteoblast proliferation. Both ERK activity and proliferation
are restored by co-treatment with the protein tyrosine
phosphatase inhibitor, vanadate. Since ERK signalling may
also be anti-apoptotic, we explored the effects of vanadate on
GC-induced apoptosis in vitro and in vivo. Apoptosis in MBA-
15.4 pre-osteoblasts increased from 6 h and remained up to
eightfold higher through 6 days of 10
K6 M dexamethasone
(Dex) treatment. Co-incubation with 10
K7 M vanadate
markedly reduced apoptosis at all time points. Vanadate
also prevented GC-induced poly-ADP-ribose polymerase
cleavage. We assessed the transcriptional proﬁles of seven anti-
apoptotic proteins (Bcl-2, Bcl-XL, inhibitors of apoptosis
protein-1 (IAP-1), IAP-2, X-linked IAP (XIAP), Fas-
associated death-domain-like IL-1b-converting enzyme-
inhibitory protein (FLIPLong) and FLIPShort) in osteoblasts
subjected tovarious stimuli using real-time quantitative PCR.
Although these anti-apoptotic genes responded to different
mitogenic conditions, Dex failed to repress their expression,
and in fact signiﬁcantly up-regulated Bcl-XL, IAP-2 and
XIAP. Dex may therefore induce apoptosis by up-regulating
pro-apoptotic gene expression. We have previously demon-
strated that rats treated with GC develop low formation
osteoporosis (bone histomorphometry and DEXA) and
skeletal fragility (breaking strength) that were largely
prevented by co-treatment with vanadate. We report here
that vertebrae from rats treated with 3.5 mg/kg per day
methylprednisolone for 9 weeks showed increased incidence
of terminal deoxynucleotidyl transferase-mediated biotin-
dUTP nick end-labelling-positive apoptotic osteocytes,
which was reduced by vanadate co-treatment. We conclude
that vanadate prevents GC-induced apoptosis of pre-
osteoblasts in vitro and osteocytes in vivo, and this may
contribute to its bone-sparing effects in vivo.
Journal of Endocrinology (2007) 195, 229–240
Introduction
Bone loss and fractures resulting from glucocorticoid (GC)
therapy is the most prevalent form of secondary osteoporosis
(Van Staa et al. 2000, Angeli et al. 2006). Skeletal health and
repair depends on replenishment of ageing cells from
precursor stem cells, efﬁcient function of mature cells and
an adequate lifespan, all of which are compromised by clinical
doses of GCs. Although GC treatment causes rapid bone loss
via transiently increasedresorption, loss of bone in response to
GC therapy is primarily due to impaired osteoblastic bone
formation (Hulley et al. 1998, Manolagas 2000, Canalis &
Delany 2002).
GCs induce apoptosis in both bone and cartilage, causing
excessive and premature loss of osteoblast precursors
(Weinstein et al. 1998, Zalavras et al. 2003), osteocytes
(Weinstein et al. 1998), articular (Van Offel et al. 2002) and
growth plate chondrocytes (Silvestrini et al. 2000, Mehls et al.
2001). Although cell proliferation and differentiation are also
negatively affected, this premature cell death may contribute
signiﬁcantly to vertebral fractures, osteonecrosis of the
femoral head, stunting of long bone growth and thinning of
articular cartilage. The loss of osteocytes might be particularly
important in terms of bone structure because this mechano-
sensor is important in the repair of bone microdamage.
However, the mechanism of GC-induced apoptotic cell death
is not known. It has been reported to depend on classical
GC:GC receptor interactions, receptor dimerization and
regulation of gene expression (Bortner & Cidlowski 2002).
Apoptosis can be triggered by multiple pathways, including
the classical extrinsic (death receptor activated) and intrinsic
(mitochondrially mediated) pathways. Common survival
strategies are deployed by most cell types (for recent reviews,
see Bortner & Cidlowski 2002, Zalavras et al. 2003) and the
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Caspase 8 is activated following death receptor clustering
or integrin dysfunction and this is prevented by decoy
proteins, the Fas-associated death-domain-like IL-1b-con-
verting enzyme-inhibitory proteins (FLIPs). Caspase 9
is activated downstream of mitochondrial permeability
transition (jT), which is mediated by cytochrome release
and regulated by pro- and anti-apoptotic Bcl-2 family
members (Adams & Cory 1998, Kelekar & Thompson 1998,
Creagh & Martin 2003). Activation of caspase 9 is prevented
by a balance being maintained between prosurvival Bcl-2
and Bcl-XL and pro-death Bad, Bid, Bim, Bax, Bak and
others. Caspases 8 and 9 are initiator caspases that in turn
activate downstream executioner caspases, such as 3, 6 and 7.
Osteoblasts and osteocytes undergoing apoptosis in response
to GCs display typical features, such as activation of caspase 3
and DNA laddering (Chua et al. 2003, Liu et al. 2004).
Executioner caspases, such as caspase 3, are blocked by a
family of inhibitors of apoptosis proteins (IAPs), many of
which are ubiquitin ligases and target the caspases for
proteasomal degradation (Deveraux & Reed 1999, Hu &
Yang 2003).
The intracellular signal transducers extracellular signal-
regulated kinases (ERK), PKB/Akt, PKA and p90
RSK are
not only important regulators of cell proliferation but also
cell survival and are thought to be involved in protection
against apoptosis (Plotkin & Bellido 2001, Tran et al. 2001,
Bortner & Cidlowski 2002, Wang et al. 2002, Dan et al.
2004, Ley et al. 2004). ERK is implicated in the regulation
of all three major anti-apoptotic families, but particularly
the FLIPs. It has also been reported that FLIP activates the
NF-kB as well as the ERK (mitogen-activated protein
kinase, MAPK) signalling pathways that have been shown to
override apoptotic signalling from Fas, tumour necrosis
factor and TNF-related apoptosis-inducing ligand (TRAIL)
death receptors (Kataoka et al. 2000, Tran et al. 2001). The
role of FLIP in cell survival is admittedly complex, with
reports implicating phosphorylated FLIP in both pro- and
anti-apoptotic signalling (Higuchi et al. 2003, Yang et al.
2003). Moreover, in immune cells, the expression of a
number of anti-apoptotic genes such as Bcl-2 has been
shown to be up-regulated (Galon et al. 2002), while many
pro-apoptotic genes were down-regulated by GCs (Galon
et al. 2002). Since the mechanism of GC-induced apoptosis
in skeletal cells remains poorly deﬁned, a more effective
approach might be to investigate mechanisms of protection
against GC-induced apoptosis. This may provide additional
insight into the mechanism(s) of death, as well as a rational
basis for the development of useful bone active drugs.
We ﬁnd that GCs mediate their inhibitory effects on
osteoblast proliferation in vitro via up-regulation of the
vanadate-sensitive dual-speciﬁcity phosphatase, MKP-1,
which profoundly represses the ERK mitogenic signalling
pathway(Engelbrechtetal.2003).Vanadate,anon-speciﬁcbut
broad-spectrum protein tyrosine phosphatase (PTP) inhibitor,
reverses this negative effect of GCs both in vitro and in vivo
(Hulley et al. 1998, 2002). Given the role of ERK in both cell
proliferation and survival, we hypothesized that GC-induced
inactivation of ERK might also affect apoptosis of osteoblasts,
and therefore set out to explore the effect of vanadate on
GC-treated osteoblasts in vitro and osteocytes in vivo.
Materials and Methods
Materials
TUNEL was performed using the In Situ Cell Death Detection
kit with metal-enhanced diaminobenzidine (DAB) stain
(Roche). Caspase-cleaved poly-ADP-ribose polymerase
(PARP)polyclonalantibodywasfromPromega.Dexamethasone
(Dex) was dissolved in ethanol as a 10
K2 M stock. U0126
(Promega) was dissolved in dimethyl sulfoxide (DMSO) to a
stock concentration of 10 mM. If inhibitors were added to cells,
control cultureswere treated withequivalent amounts of ethanol
and/or DMSO. Foetal calf serum (FCS) was from Delta
Bioproducts (Johannesburg, Republic of South Africa). All
other chemicals including tissue culture media, Dex and sodium
orthovanadate were purchased from Sigma.
Cell culture
MBA-15.4 mouse bone marrow stromal cells were a kind gift
from Prof. S Wientroub, Tel Aviv University, Israel. They
express osteoblastic markers such as alkaline phosphatase and
collagen type I, but very low levels of parathyroid hormone
receptors, in vitro and can be induced to produce bone in vivo
(Benayahu et al. 1989, Fried et al. 1993). MBA-15.4 cells were
grown in bicarbonate-buffered Dulbecco’s modiﬁed Eagle’s
medium (DMEM) with 10% (v/v) heat-inactivated FCS,
100 U/ml penicillin and 100 mg/ml streptomycin. For
experiments, 70% conﬂuent cells were lifted with a cell
scraper and seeded in 24-well plates on cover glasses (for
detection of apoptosis) or 100-mm culture dishes (all other
experiments). Medium was changed to DMEM with 1% FCS
(v/v) for 24 h to serum starve and synchronize the cell cycle
of the cells prior to 20% FCS (v/v) stimulation. The MEK
inhibitor, U0126, was added 30 min before 20% FCS (v/v)
stimulation to a ﬁnal concentration of 10 mM in experiments
where the effect of MAPK inhibition on gene expression was
ascertained. In cell culture experiments involving Dex
treatment, cells were cultured to at least 50% conﬂuence in
medium with 10% FCS (v/v) prior to the addition of Dex,
dissolved in ethanol, to a ﬁnal concentration of 1 mM. Cells
treatedwith Dex for !3daysweretreated once and for 6days
were treated on day 1 and again on day 3.
In vivo study
The treatment protocol for the in vivo rat study was approved
by the Ethics Committee and the Animal Research
Committee, University of Stellenbosch and complies with
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in detail in Hulley et al. (2002) and vertebral bones from this
study were preserved for the current apoptosis investigation.
In brief, the study was carried out on 3.5- to 4-month-old
female Sprague–Dawley rats weighing on average 260 g at the
beginning of the experiment. They were maintained on a
12-h light/darkness cycle with free access to food (Rat and
Mouse Breeder Feed, Animal Specialities, Pty, Ltd, Klapmuts,
Cape Town, South Africa) and water. Diet was assessed to
ensure adequate intake of calcium and vitamin D for bone
growth (18 g/kg Ca
2C, 8 g/kg phosphorus, 1000 IU/kg
vitamin D). Treatment groups (nZ10) over 9 weeks were
as follows: C, sham-injected once daily, 5 days/week; S,
3.5 mg/kg per day methylprednisolone (Solu-medrol)
injected subcutaneously; V, 0.5 mg/ml sodium orthovanadate
continuously in drinking water plus sham injection and SV,
methylprednisolone plus vanadate. Sodium orthovanadate
was dissolved at 0.5 mg/ml in sterile, deionized water and
corrected to pH 6.0–7.0 with ascorbic acid. All other rat
groups received the same amount of ascorbic acid in their
drinking water, corrected to neutral pH with sodium
hydroxide. Rats in the vanadate and steroid plus vanadate
treatment groups received only vanadate-supplemented water
at all times throughout the 9-week study. Vanadate intake was
assessed by determining serum vanadium levels at 9 weeks by
inductively coupled plasma-mass spectrometry (Hulley et al.
2002). Water intake was not measured for the different groups
but was sufﬁcient for the rats to be weight matched to their
control groups after 9 weeks. Rats were weighed twice or
thrice per week during the study and showed a slight but
steady weight gain throughout. After killing the rats with
pentobarbital, the vertebrae were removed and stored in 70%
ethanol at 4 8C. One of the lumbar vertebrae (L5) from
each of ﬁve rats per treatment group was removed, ﬁxed
in modiﬁed Millonig’s solution (100 ml 37% (v/v)
formaldehyde solution, 900 ml distilled water, 18.6g
NaH2PO4,4 .2 g NaOH, 5 g sucrose; pH 7.4 at room
temperature) for 24 h, and then decalciﬁed using serial
changes of 10% EDTA (w/v), pH 7.0a t48C over 2 weeks,
embedded in wax and sectioned at 5 mm. Matching sections
from the vertebral bodies (embedded disc side down) were
assessed for apoptotic osteocytes using the Terminal deoxy-
nucleotidyl transferase-mediated biotin-dUTP nick end-
labelling (TUNEL) method.
Apoptosis assay
TUNEL was used to detect apoptotic cells in vitro and in rat
sections, according to the manufacturer’s instructions. Cell
death was determined by counting, blinded to the treatment
groups, the number of cells containing nuclei with apoptotic
morphology that were also stained dark brown with DAB.
Cells grown on cover glasses were ﬁxed with freshly prepared,
ice-cold 4% paraformaldehyde (w/v) in PBS, pH 7.4, for
30 min at room temperature. Cells were pretreated by
blocking endogenous peroxidases and were permeabilized
in 0.2% Triton-X (v/v) on ice for 2 min, prior to TUNEL
staining according to the manufacturer’s protocol for adherent
cells, cell smears and cytospin preparation, but with TUNEL
reaction overnight at 4 8C, followed by metal DAB-enhanced
peroxidase detection. Positive controls were prepared by
pretreating cells with DNase according to the manufacturer’s
instructions prior to TUNEL staining, and terminal
transferase enzyme was omitted from negative controls.
Sections cut from decalciﬁed parafﬁn-embedded specimens
of rat vertebrae were dewaxed. They were then treated for
10 min with 3% H2O2 (v/v) in methanol to inactivate
endogenous peroxidase and processed according to the
manufacturer’s method for difﬁcult sections, incorporating
microwave pretreatment in citrate buffer, overnight TUNEL
labelling at 4 8C, followed by metal DAB-enhanced per-
oxidase detection. Both cultured cells and treated sections
were counterstained with 1% methyl green.
Counting of apoptotic cells
Apoptotic cells were counted by a single researcher (M M C),
blinded to the study groups. TUNEL staining can lead to
overestimation or underestimation of the frequency of
apoptosis but should not lead to an inaccurate relative
assessment between treatment groups. Using standard bright
ﬁeld microscopy, cells with both dark brown nuclear stain and
apoptotic morphology were interpreted as positive. Mitotic
pairs sometimes stained positively and were excluded. On
cover glasses G120 ﬁelds were counted. In the rat sections,
osteocytes were identiﬁed inside cortical lacunae and G25
ﬁelds were examined in each section from ﬁve rats per group
at 250! magniﬁcation.
Caspase activity
Apoptosis in vitrowas conﬁrmed in these cells by the detection
of a caspase-cleaved substrate, using an antibody that only
detects the large 89 kDa caspase-cleaved fragment of PARP.
PARP fragments stained dark brown, using metal DAB-
enhanced peroxidase detection, and were counted as above.
Speciﬁcity of the antibody was controlled by detection of a
single w90 kDa band on western blot of lysates from
osteoblasts undergoing mass apoptosis following treatment
with 40 mg/ml cycloheximide. Immunostaining on cover
glasses was also carried out using secondary antibodyonly and
on a serum-deprived, heavily apoptotic population as a
positive control.
Western blotting
Cells were treated for 24 h with 40 mg/ml cycloheximide,
1 mM Dex, 0.1 mM sodium orthovanadate, 10 mm U0126 or
combinations of these. Cell lysates were prepared as
previously described (Hulley et al. 1998) and equal protein
samples subjected to SDS-PAGE electrophoresis, followed by
transfer to Polyvinylidene ﬂuoride (PVDF) membrane,
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PARP antibody at 4 8C overnight. Detection was performed
using horse radish peroxidase-conjugated secondary antibody
and enhanced chemiluminescence reagents from Amersham.
Real-time quantitative PCR (rtqPCR)
Total RNA extraction from MBA-15.4 osteoblasts, reverse
transcription of DNase-treated RNA and rtqPCR were
performed as described previously (Engelbrecht et al. 2003).
Brieﬂy, gene transcript levels of the GC-insensitive house
keeping gene, the glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and the anti-apoptotic mouse genes
Bcl-2, Bcl-XL, IAP-1, IAP-2, X-linked IAP (XIAP),
FLIPLong and FLIPShort were quantiﬁed by rtqPCR on a
LightCycler (Roche Diagnostic Systems). Hot start PCR was
performed according to the manufacturer’s instructions, with
a ﬁnal concentration of 3–5 mM MgCl2 and 0.5 mM primer
(LightCycler – FastStart DNA Master SYBR Green I,
Roche). The various gene transcript levels of the anti-
apoptotic genes in treated samples were quantiﬁed and
compared with the respective transcript levels in untreated
controls using the relative standard curve method (Applied
Biosystems, division of Perkin–Elmer, Foster City, CA,
USA). A total of three independent experimental repeats
were performed, and repeat assessments of cDNA from each
experiment were also made.
The following primer pairs were used: mouse GAPDH
(accession no. NM_008084) forward: 50-ATTGTCAG-
CAATGCATCCTG-30, reverse: 50-ATGGACTGTGGT-
CATGAGCC-30; mouse Bcl-2 (accession no. M16506)
forward: 50-ACTTCTCTCGTCGCTACCGT-30, reverse:
50-CTGTTGACGCTCTCCACACA-30;m o u s eB c l - X L
(accession no. L35049) forward: 50-CGTAGACAAGGA-
GATGCAGG-30, reverse: 50-TCAGGAACCAGCGGTT-
GAAG-30; mouse IAP-1 (accession no. U88908) forward:
50-AAGTGTGTATGGACCGAGAG-30, reverse: 50-GG-
ACCATTAGTCTTGTTCAG-30; mouse IAP-2 (accession
no. U88909) forward: 50-TGTGTATGGACAGAGAGGTT-
30, reverse: 50-CAGCTTCTGATGTCCAACAA-30; mouse
XIAP (accession no. NM_009688) forward: 50-ATACG-
GAGGATGAGTCAAGT-30, reverse: 50-GGTTGAACG-
TAATGACGGTG-30;m o u s eF L I P Long (accession no.
U97076) forward: 50-CTGTGTCTGCCGAGGTCATT-30,
reverse: 50-AACCGCCTCACTCTGTAGAG-30 and mouse
FLIPshort (accession no. XM_124038) forward-1: 50-GCCT-
GAAGAACATCCACAGA-30, reverse-1: 50-TCTCTGA-
GACTGGTTCATGC-30,f o r w a r d - 2 :5 0-CTGAACAGA-
GACTCCTTAGA-30, reverse-2: 50-AGGAGGCTGAAG-
CAAGAGGA-30. As a negative control for DNA contami-
nation,puriﬁedmRNAwasusedastemplateforPCRwithall
oftheabove-mentionedprimer pairs.NoPCRproductswere
detected. To further eliminate possible variation in rtqPCR
due to the presence of residual contaminating DNA, the
primer pairs were designed to span intron/exon boundaries
where possible. The identities of all PCR products were
conﬁrmed by sequencing.
Statistical analysis
Results are given as the meanGS.E.M.o rGS.D. as indicated.
Data were analysed using GraphPad Prism v 2.01 (GraphPad
Software Inc., San Diego, CA, USA) by one-way ANOVA
with Dunnett’s post hoc test or Tukey’s post hoc test for multi-
group comparisons. Differences were considered statistically
signiﬁcant at P!0.05.
Results
Dex induces apoptosis in osteoblasts in vitro
Treatment of MBA-15.4 osteoblasts (Fig. 1) with high-dose
Dex induced typical apoptotic features, including cell
shrinkage, caspase cleavage of PARP (Fig. 1D) and DNA
fragmentation (Fig. 1E and F). Only MBA-15.4 osteoblasts
with both dark brown stain and apoptotic morphology (cell
shrinkage, condensed chromatin, formation of apoptotic
bodies) were interpreted as positive.
Prevention of GC-induced apoptosis by vanadate in vitro
MBA-15.4 murine osteoblasts were treated with doses of Dex
ranging from 1 nM to 10 mM (results not shown), for periods
of 6 h to 6 days. A maximum increase in apoptosis, at all time
points tested, was achieved with 0.1 mM and 1 mM Dex. Basal
apoptosis, as detected by TUNEL, is low (below 0.5%) in this
cell line. This rose to a maximum of 2.5% with Dex treatment
and this level of apoptosis was maintained throughout 6 days
of treatment. We have previously reported that the tyrosine
phosphatase inhibitor, sodium orthovanadate, prevents Dex-
induced inhibition of ERK activity and dysregulation of
osteoblast proliferation in rats, and strongly protected against
GC-osteoporosis (Hulley et al. 1998, 2002, Engelbrecht et al.
2003). Since ERK is also a prosurvival kinase, we tested the
effect of concurrent vanadate treatment on GC-induced
apoptosis of osteoblasts and found effective protection at 6 h
(Fig. 2A), 3 days (Fig. 2B) and 6 days (Fig. 2C).
Dex induces cleavage of PARP in osteoblasts
To conﬁrm these results using a different method, we
performed immunocytochemistry (ICC) with an antibody
detecting the apoptosis-speciﬁc 89-kDa C-terminal caspase
cleavage product of PARP. PARP cleavage, detected by ICC,
was almost absent in control cultures but was readily detected
in 3% of cells following 6 days of Dex treatment (Fig. 2D), in
agreement with TUNEL data (Fig. 2C). Once again,
vanadate co-treatment strongly reduced the number of
apoptotic cells, indicating protection against both caspase
activation and DNA fragmentation.
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prosurvival genes in MBA-15.4 osteoblasts
Since 6 days of Dex treatment consistently produced the
highest level of osteoblast apoptosis, we tested the effect of
Dex, alone and in combination with vanadate, on expression
of the panel of prosurvival genes at multiple time points over
6d a y s( Fig. 3). Unexpectedly, Dex did not down-regulate
expression of any prosurvival genes and in fact up-regulated
several. The expression of Bcl-XL was increased approxi-
mately sevenfold within 24 h of Dex treatment and this
remained approximately ﬁvefold up-regulated throughout
6 days of treatment. IAP-2 and XIAP transcription was
reproducibly doubled, with IAP-2 showing up-regulation as
early as 4 h after Dex treatment before tapering off after 24 h.
XIAP transcription levels were doubled at 24 h but remained
elevated for 3 days. The transcript levels of anti-apoptotic
proteins Bcl-2, IAP-1, FLIPLong and FLIPShort were not
detectably altered by Dex treatment. Interestingly, treatment
of cells with vanadate alone produced no changes in
expression of these prosurvival genes at any time point.
Co-treatment of osteoblastic cells with both Dex and
vanadate produced no signiﬁcant alteration in the expression
patterns observed with Dex alone, indicating that Dex and
vanadate in this context are acting via separate pathways.
Mitogen withdrawal induces osteoblast apoptosis and regulates
prosurvival gene expression
Given the unexpected up-regulation of prosurvival genes by
Dex, and since vanadate appeared to promote survival via the
mitogenic ERK and PKB pathways, we set out to identify
prosurvival signalling molecules in osteoblasts that are highly
regulated by changing mitogenic conditions. MBA-15.4
osteoblasts were subjected to serum withdrawal for 24 h in
order to deplete mitogenic growth factors. This caused a
30-fold increase in apoptosis, detected with both TUNEL
and caspase-cleaved PARP antibody (Fig. 4A). Speciﬁcity of
this antibody was conﬁrmed by western blot using a strong
pro-apoptotic stimulus, 40 mg/ml cycloheximide, but please
note that we were unable to detect the low levels of apoptosis
seen with Dex, alone or in combination with inhibitors
(Fig. 4B). Real-time quantitative PCR showed that serum
withdrawal-induced apoptosis was associated with a strong,
transcriptional up-regulation of a panel of prosurvival
molecules (Fig. 4C). However, in contrast to Dex treatment,
Bcl-2 expression was approximately tenfold increased,
whereas Bcl-XL was unchanged. FLIPLong and FLIPShort
were increased approximately seven- and fourfold respectively
and IAP-1 and IAP-2 both increased approximately threefold.
Both FLIP isoforms have previously been shown to be
regulated by ERK activity (Wang et al. 2002). To investigate
this in osteoblasts, the expression levels of FLIPLong and
FLIPShort were quantiﬁed in MBA-15.4 cells mitogenically
stimulated with 20% FCS (following 24 h of reduced serum
culture to synchronize cell cycle and mitogenic response).
FLIPLong and FLIPShort transcript levels were both approxi-
mately tenfold up-regulated in response to mitogen stimu-
lation (Fig. 4D). This increase was halved for both FLIPLong
and FLIPShort when cells were co-treated with the MEK
inhibitor, U0126. This inhibitor was used at 10 mM, a
concentration validated in this cell line not only to inhibit
ERK phosphorylation but also to inhibit serum-stimulated
osteoblast proliferation (Engelbrecht et al. 2003). Therefore,
the FLIPs are highly mitogen-sensitive in osteoblasts,
responding very strongly to mitogenic stimulation and more
weakly to mitogen withdrawal. Up-regulation by serum
Figure 1 Morphology of apoptotic MBA-15.4 osteoblasts. Healthy
MBA-15.4osteoblasts (A–C)weretreatedwithdexamethasone(D–F
and J) and assessed by immunocytochemistry for cleaved PARP
(B and D) and by TUNEL (C, E–H). Normal morphology is shown
using methylene blue stain (A). Apoptotic cells were identiﬁed on
the basis of both positive staining and typical morphological
changes of the cells (arrows; D–F). TUNEL staining was controlled
using cover glasses pretreated with DNase to create breaks in the
DNA of healthy cells (G and H), or as a negative control, highly
apoptotic serum-starved cells with TUNEL but no terminal
transferase enzyme (I). This produced a lighter stain than true
apoptosis and no change in morphology (compare F with H), or no
staining but apoptotic morphology with condensed, rounded cells
(arrowhead; I). Secondaryantibody only control (cPARP protocol) is
shown for cells treated with dexamethasone (J).
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osteoblasts.
Vanadate has anti-apoptotic effects in vivo
To assess the effect of vanadate on GC-induced apoptosis
in vivo, we examined the effect of vanadate in a rat model
of GC-induced osteoporosis. Rats treated with high-dose
GC (3.5 mg/kg per day methylprednisolone for 9 weeks)
develop osteoporosis which, as shown by our group
(Hulley et al. 2002) and others (Ortoft et al. 1995, Ortoft
& Oxlund 1996), is characterized by a severe inhibition of
new bone formation and a decrease in BMD, bone size and
bone strength. Co-treatment with vanadate largely pre-
vented these GC effects (Hulley et al. 2002). Precise
identiﬁcation of osteoblasts is difﬁcult in histological
sections unless double-staining protocols are used and we
therefore analysed apoptosis in osteocytes which occupy
lacunae. Employing TUNEL, GC-induced apoptosis was
detectable in both osteocytes (Fig. 5A) and bone-lining
cells (Fig. 5B). Quantiﬁcation revealed between two- and
ﬁvefold increases in the number of apoptotic osteocytes
(Fig. 5C; P!0.05 versus control). Rats co-treated with
vanadate were indistinguishable from untreated controls,
indicating protection of osteocytes from GC-induced
apoptosis over a period of 9 weeks (Fig. 5C).
Discussion
GC-induced osteoporosis is characterized by decreased bone
formation and reduced osteoblast numbers, the latter resulting
from a combination of impaired recruitment and proliferation
of immature osteoblasts, transdifferentiation of osteoblasts to
adipocytes and accelerated osteoblast apoptosis (Manolagas
2000, Canalis & Delany 2002). In addition to induction of
apoptosis in primary osteoblast cultures, GCs have also been
shown to increase apoptosis in several cell lines including
MLO-Y4 osteocytic cells (Ahuja et al. 2003), MC3T3-E1,
OCT-1 and C3H10T1/2 osteoblastic cells (Chen et al. 2002,
Ahuja et al. 2003, Liu et al. 2004). GCs have, however, also
been shown to protect primary osteoblasts and osteoblastic
cell lines (MC3T3-E1, MG63) from apoptosis, depending on
culture conditions (Zalavras et al. 2003). Up-regulation of the
anti-apoptotic proteins Bcl-2 or Bcl-XL by GCs has been
reported in MC3T3-E1 osteoblastic cells (Chua et al. 2003)
and lymphocytes (Galon et al. 2002), and this may provide a
mechanism for GC resistance to apoptosis in some
transformed cell lines. Cell lines like MBA-15.4 and MLO-
Y4 can, however, be reliably induced to respond to GCs with
increased apoptosis and provide useful models for preliminary
studies of the primary tissue.
The present study conﬁrms previous reports of
GC-induced apoptosis, demonstrating that high-dose
Figure2 Effect ofdexamethasoneandvanadateonapoptosisin MBA-15.4osteoblasts.MBA-15.4 osteoblasts,
grown in 10% FCS, were treated for 6 h, 3 days and 6 days with 10
K6 M Dex and/or co-treated with 10
K7 M
vanadate (VO4). Dex was added every 3 days and vanadate daily. Apoptotic cells were identiﬁed on the basis
of morphological changes and either TUNEL staining (A–C) or cleaved PARP immunocytochemistry (D). Total
cell countswere not performed in the ﬁrstset of experiments(A), so these data are expressedas apoptotic cells
per ﬁeld. Results (meanGS.D.) are the average of at least four independent experimental repeats, exceptwhere
otherwise stated. *P!0.05, **P!0.01.
M M CONRADIE, H DE WET and others . Vanadate prevents GC-induced apoptosis in bone 234
Journal of Endocrinology (2007) 195, 229–240 www.endocrinology-journals.org(100 nM and 10 mM) Dex induces apoptosis of MBA-15.4
mouse osteoblasts within 6 h of treatment. The number of
apoptotic osteoblasts detected by TUNEL stain (DNA
fragmentation) increased from very low basal levels to 2–3%
after 6 h of GC treatment and remained at this level
throughout 6 days of continuous exposure. Similar increases
in cell death were seen using immunocytochemical detection
of the 89 kDa caspase-cleaved product of PARP (poly ADP-
ribose polymerase). The total number of dead cells following
Dex treatment did not exceed 10%, although higher levels
(30%) could be induced by 24-h serum deprivation. This low
level of GC-induced apoptosis correlates well with levels of
apoptosis in vivo in patients with steroid osteoporosis, reported
as 5% osteocytes (Weinstein et al.1 9 9 8 ). Moreover, employing
TUNEL staining on histological sections from the vertebrae of
rats treated with 3.5 mg/kg per day methylprednisolone for 9
weeks,wefoundsimilarincreasesinosteocyteapoptosis.Therat
model of steroid-induced osteoporosis has been well docu-
mented, although rats have been reported to be relatively
resistant to corticosteroid-induced bone damage (Binz et al.
Figure 3 The anti-apoptotic genes Bcl-XL, XIAPand IAP-2 are up-regulated by dexamethasone in osteoblasts.
Real-time quantitative PCR was used to quantify the expression of seven anti-apoptotic genes in response to
treatment with Dex alone (open squares), vanadate alone (closed diamonds) or Dex and vanadate in
combination (closed circles) in the MBA-15.4 mouse osteoblastic cell line. Osteoblasts were treated with
1 mM Dex and/or 0.1 mM vanadate for 30 min to 6 days while growing in 10% FCS. Levels of the
anti-apoptotic genes and the dexamethasone-insensitive housekeeper, GAPDH, in treated samples were
quantiﬁed and compared to the respective transcript levels in untreated controls using the relative standard
curve method. A total of three independent experimental repeats were performed, and repeat assessments of
cDNA from each experiment were also made. *P!0.05, **P!0.01.
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in vivo studies including our own (Hulley et al.2 0 0 2 ), marked
inhibition of bone formation (Goulding & Gold 1986, 1988,
Jowell et al.1 9 8 7 , Unoki 1995, Ortoft & Oxlund1996, Shen et
al.1 9 9 7 , Ortoft et al.1 9 9 9 ), decrease in BMD (Lindgren &
DeLuca1983,Goulding&Gold1986,Ortoft&Oxlund1996)
andcorticalstrength(Ortoftetal.19 95 ,1999,Ortoft&Oxlund
1996)havebeenreported,aswellasimpairedgrowthinjuvenile
rats (Ortoft et al.1 9 9 8 ).
Although osteoblast/osteocyte apoptosis is a well-estab-
lished feature of GC-induced osteoporosis, the molecular
mechanisms that underlie this process remain poorly under-
stood. Proteins comprising the MAPK family constitute
importantmediatorsofsignaltransduction processesthatserve
to coordinate cellular response to a variety of extracellular
stimuli. Of the three major mammalian MAPK subfamilies
described, ERK, cJun-N-terminal kinases (JNK) and p38
kinases,theERKpathwayhasbeenshowntoplayamajor role
in regulating cell growth and differentiation. The role of
MAPK signalling pathways in regulating apoptosis during
conditions of stress has also been widely investigated. Many
(Tran et al. 2001, Bortner & Cidlowski 2002, Ley et al. 2004),
Figure 4 Serum deprivation induces apoptosis in MBA-15.4 osteoblasts and regulates prosurvival genes.
Osteoblasts were cultured until 70% conﬂuence in standard medium with 10% FCS and then medium was
replaced with either serum-free medium for 24 h (A, C and D), medium containing 1% serum (v/v) (C),
medium containing 10% FCS (v/v) with or without 40 mg/ml cycloheximide (CHx), 10 mM Dex, 0.1 mM
vanadate,10 mMMEKinhibitor,U0126orcombinations asindicated(B), or mediumcontaining20% FCS(v/v)
with or without 10 mM MEK inhibitor, U0126 (D). Cells grown on cover glasses were assessed by
immunocytochemistry for cleaved PARP or TUNEL and the number of apoptotic and total cells counted (A).
SpeciﬁcityofthecleavedPARPantibody wascontrolledbywesternblotdetectionof asinglew90 kDabandin
lysates of cells undergoing mass apoptosis following cycloheximide treatment (B). Real-time quantitative PCR
was performed on mRNA extracted from cells grown on 10-cm dishes to compare expression of a panel of
prosurvival genes following serum starvation (C). A more detailed rtqPCR analysis of the responses of FLIPLong
(open bars) and FLIPShort (ﬁlled bars) to serum stimulation (20% FCS), treatment with the MEK inhibitor,
U0126, for 30 min prior to 20% FCS (v/v) stimulation, total (0%) and partial (1%) reduction in serum was
performed (D). Real-time analysis was performed in duplicate and is expressed relative to untreated controls
and normalized to GAPDH. Each ﬁgure represents the average of two independent experimental repeats.
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such studies have supported the general view that activation
of the ERK pathway mediates survival signals which
counteract pro-apoptotic effects associated with JNK and
p38 activation. Pharmacological inhibition of ERK activation
(e.g. employing the MEK inhibitor U0126) has been shown
to enhance chemotherapy-induced apoptosis of the lung,
ovarianandbreastcarcinoma celllines (MacKeiganetal.2000,
McDaid & Horwitz 2001). In skeletal tissue, ERK has been
showntomediatesomeoftheprotectiveanti-apoptoticeffects
of bisphosphonates (Plotkin et al. 1999, Plotkin & Bellido
2001, Van Offel et al. 2002), calcitonin (Plotkin et al. 1999),
activated transforming growth factor-b (Karsdal et al. 2002),
(non-steroidal anti-inﬂammatory drugs NSAIDs; Yoon et al.
2003) and others. Furthermore, we have previously shown
that ERK activity is profoundly impaired by high-dose GC,
mediated in part by rapid and sustained up-regulation of
MKP-1 (Hulley et al. 1998, Engelbrecht et al. 2003). This
vanadate-sensitive dual-speciﬁcity phosphatase is an immedi-
ate early gene product, normally involved in negative
feedback inhibition of the MAP kinases (Slack et al. 2001,
Lasa et al. 2002). Taken together, these observations suggest
that repression of the ERK pathway by GCs might play a role
in GC-induced apoptosis of skeletal cells.
The non-selective PTP inhibitor, vanadate, protected
MBA-15.4 osteoblasts against apoptosis, induced by 6-h,
3-day and 6-day treatment with high-dose Dex. Vanadate
alone had no effect on apoptosis. In rats, a threefold increase
in osteocyte apoptosis induced by high-dose GC exposure for
9 weeks was largely abrogated by co-treatment with vanadate.
While these studies supported a role for the ERK pathway in
GC-apoptosis, the primary site of vanadate’s protective action
remained unclear. ERK could be directly inactivated by
the vanadate-sensitive phosphates, MKP-1, as alluded to
previously (Hulley et al. 1998, Engelbrecht et al. 2003), and
MKP-1-induced dephosphorylation of ERK has been shown
to be essential for nitric oxide-induced apoptosis of certain
cells (Pervin et al. 2003). Alternatively, ERK could be
indirectly protected by vanadate since it is downstream of
kinase cascades that are primarily activated by tyrosine
phosphorylation. Vanadate-sensitive PTPs like PTP-1B
inactivate ERK and Akt/PK B indirectly by dephosphorylat-
ing upstream growth factor receptors and insulin receptor
substrates, thereby preventing tyrosine-dependent docking of
molecules like shc, grb2 or PI3-kinase (Neel & Tonks 1997,
Elchebly et al. 1999, Galic et al. 2005). Like ERK, PKB has
been shown to phosphorylate and target pro-apoptotic
molecules for proteasomal destruction (Qi et al. 2006). PKB
also phosphorylates and stabilizes anti-apoptotic proteins like
XIAP (Dan et al. 2004).
In order to explore the possible downstream effectors of
GC-induced apoptosis further, we employed rtqPCR to
examine the expression of the major families of prosurvival
genes (Bcl-2, Bcl-XL, IAP-1, IAP-2, XIAP, FLIPLong and
FLIPShort) in osteoblasts subjected to high-dose Dex.
Contrary to expectations, Dex did not repress expression of
any of the candidate protective genes. Instead, Dex
up-regulated the expression of Bcl-XL, IAP-2 and XIAP,
while the transcript levels of the anti-apoptotic proteins
Bcl-2, IAP-1, FLIPLong and FLIPShort were unaltered by Dex
treatment. GCs cause death of osteoblasts, so the up-regula-
tion of prosurvival genes by Dex is difﬁcult to explain, but
may indicate a compensatory, survival strategy that cells
deploy when exposed to high-dose Dex. Vanadate alone
Figure 5 The in vivo effect of vanadate on osteocyte apoptosis in
rats treated for 9 weeks with glucocorticoid. Rats received either
daily sham injections, injections of 3.5 mg/kg per day methyl-
prednisolone, sodium orthovanadate at 0.5 mg/ml continuously in
their drinking water or a combination of vanadate and steroid
injections (SCV) (as described in Materials and Methods). L5
vertebrae were decalcifed, wax-embedded and matching sections
were TUNEL stained. TUNEL-positive osteocytes were identiﬁed
inside cortical lacunae (A) and apoptotic bone-lining cells also
noted (B). High-dose GC treatment induced a signiﬁcant increase in
apoptotic osteocytes (C). Incidence in rats treated with vanadate
alone or in combination with GC was indistinguishable from
controls. Sectionswere analysed from ﬁve animals in eachgroup by
a single investigator (MMC) blinded to the treatments. Data are
expressed relative to total osteocyte number GS.D.* P!0.05.
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This is not unexpected since vanadate also had no effect on
the rate of apoptosis. Moreover, we have previously reported
that vanadate alone does not signiﬁcantly alter ERK levels in
MBA-15.4 cells, although it effectively protects ERK against
GC-induced inactivation (Hulley et al. 1998, Engelbrecht
et al. 2003). Vanadate also did not signiﬁcantly alter the
up-regulation of genes induced by Dex, suggesting that this is
not an ERK-mediated process.
Given the role of ERK in both cell proliferation and
survival, we also explored the effects of mitogen withdrawal
and mitogen stimulation on osteoblast prosurvival gene
expression. Subjecting MBA-15.4 osteoblasts to mitogen
withdrawal by culturing cells in the absence of serum for 24 h,
markedly (sevenfold) stimulated apoptosis. Analogous to,
although different from the observed effects of Dex exposure,
mitogen withdrawal also did not decrease expression of any
prosurvival genes, and instead resulted in increased transcrip-
tion of the anti-apoptotic proteins Bcl-2, IAP-1, IAP-2,
FLIPLong and FLIPShort. Interestingly, expression of FLIPLong
and FLIPShort was stimulated with 20% FCS and this increase
was halved when cells were treated with the MEK inhibitor
U0126, for 30 min prior to mitogen stimulation, suggesting a
regulatory role for MEK–ERK in FLIP gene expression in
osteoblasts. Taken together, these results do not support a role
for GC-induced down-regulation of prosurvival genes.
Instead, GC-apoptosis appears more likely to result from
direct or indirect effects on pro-apoptotic molecules,
including their phosphorylation and proteasomal destruction
– a process that can be mediated by MEK–ERK (Tran et al.
2001, Ley et al. 2004).
We report here that vanadate is strongly anti-apoptotic
in vivo, protecting rat vertebral osteocytes from GC-induced
apoptosis over a period of 9 weeks. The mechanism of action
of vanadate in vivo is unclear. It has been described in several
animal models (Heyliger et al. 1985, Meyerovitch et al. 1987,
Brichard et al. 1988) and also in diabetic patients (Cohen et al.
1995) to act as an insulin mimic via its inhibition of PTPs in
the insulin signalling pathway (Zinker et al. 2002). Vanadate
enhances and sustains action of PI3-kinase and PKB/Akt,
with anti-apoptotic effects in some cell types (Gerling et al.
2004). An alternative mechanism of action could be the
inhibition by vanadate of several ATPases, including both
plasma and endoplasmic reticulum membrane Ca-ATPases
and plasma membrane NaK-ATPases (Ortiz et al. 1984,
Garrahan & Rega 1988), although there are no reports of this
having anti-apoptotic effects. In contrast, long-term disrup-
tion of membrane pumps usually induces apoptosis (Zhou
et al. 1998). Vanadate also inhibits the multi-drug transporter
protein, P-glycoprotein (Urbatsch et al. 1995, Taguchi et al.
1997), responsible for exporting toxic chemicals from cells
and is known to disrupt the transport functions of most
ATP-binding casette proteins (Terasaka et al. 2003). However,
it seems unlikely that blocking a protective clearance
mechanism would be protective over a period of 9 weeks,
and in support of this, P-glycoprotein knockout mice are
symptom free but hypersensitive to environmental toxins
(Schinkel et al. 1994).
To conclude, vanadate protects MBA-15.4 mouse osteo-
blasts in vitro and rat osteocytes in vivo from apoptosis induced
by high-dose GC. This protective mechanism may involve
both ERK and PI3-Kinase pathways but does not involve
transcriptional up-regulation of any major anti-apoptotic
proteins in osteoblasts. Dex does not down-regulate
transcription of these prosurvival proteins and in fact
up-regulates several. GC and vanadate are therefore more
likely to converge on the transcription of pro-apoptotic
proteins and/or the post-transcriptional regulation of either
pro- or anti-apoptotic mediators.
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